A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508267-69-00

Acronym

XB002-101

Enrollment

222

Registered

2024-09-09

Start date

2023-08-11

Completion date

2025-03-10

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and combination treatment will also be evaluated with nivolumab in NSCLC, and esophageal SCC, and for XB002 plus bevacizumab in EOC., SCCHN, Subjects with Aadvanced solid tumors for whom life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. Single-agent XB002 will be evaluated up to 10 tumor types

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Belgium, France, Italy, Netherlands, Spain

Outcome results